| ■ 영문 제목 : Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market 2023-2027
|
 | ■ 상품코드 : IRTNTR72445-23
■ 조사/발행회사 : Technavio
■ 발행일 : 2023년 2월
■ 페이지수 : 약120
■ 작성언어 : 영문
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (24시간 이내)
■ 조사대상 지역 : 북미, 유럽, 아시아, 기타 지역
■ 산업 분야 : 의약품
|
■ 판매가격 / 옵션
(부가세 10% 별도)
| Single User (1명 열람용) | USD2,500 ⇒환산￦3,375,000 | 견적의뢰/주문/질문 |
| Enterprise License (동일기업내 공유가능) | USD4,000 ⇒환산￦5,400,000 | 견적의뢰/주문/질문 |
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
|
Technavio사의 본 연구 보고서는 세계의 혈관 내피 성장 인자 (VEGF) 억제제 시장 규모가 2023년과 2027년 사이에 10,400.61백만 달러에 이르며, 예측 기간 중 연평균 성장률은 7.76%가 될 것으로 전망하고 있습니다. 본 보고서는 세계의 혈관 내피 성장 인자 (VEGF) 억제제 시장을 조사 대상으로 하여, 개요, 시장 현황, 시장 규모 예측, 과거 시장 규모, Five Force 분석, 용도별 (종양, 안과) 분석, 종류별 (VEGF-A 억제제, VEGF-B 억제제, VEGF-C 억제제, VEGF-D 억제제) 분석, 고객 현황, 지역별 (북미, 유럽, 아시아, 미국, 캐나다, 영국, 독일, 일본, 기타 지역) 분석, 기업 분석 등의 내용을 수록하고 있습니다. 덧붙여 본 조사 자료는 AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bausch Health Co Inc., Bayer AG, Bristol Myers Squibb Co., Clovis Oncology, Eisai Co. Ltd., Eli Lilly and Co., Exelixis Inc., F. Hoffmann La Roche Ltd., LG Chem Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA 등의 기업 정보를 포함하고 있습니다.
・개요
・시장 현황
・시장 규모 예측
・과거 시장 규모
・Five Force 분석
・세계의 혈관 내피 성장 인자 (VEGF) 억제제 시장 규모 : 용도별
- 종양에 사용되는 VEGF 억제제의 시장 규모
- 안과에 사용되는 VEGF 억제제의 시장 규모
・세계의 혈관 내피 성장 인자 (VEGF) 억제제 시장 규모 : 종류별
- VEGF-A 억제제의 시장 규모
- VEGF-B 억제제의 시장 규모
- VEGF-C 억제제의 시장 규모
- VEGF-D 억제제의 시장 규모
・고객 현황
・세계의 혈관 내피 성장 인자 (VEGF) 억제제 시장 규모 : 지역별
- 북미의 혈관 내피 성장 인자 (VEGF) 억제제 시장 규모
- 유럽의 혈관 내피 성장 인자 (VEGF) 억제제 시장 규모
- 아시아 혈관 내피 성장 인자 (VEGF) 억제제 시장 규모
- 미국의 혈관 내피 성장 인자 (VEGF) 억제제 시장 규모
- 캐나다의 혈관 내피 성장 인자 (VEGF) 억제제 시장 규모
- 영국의 혈관 내피 성장 인자 (VEGF) 억제제 시장 규모
- 독일의 혈관 내피 성장 인자 (VEGF) 억제제 시장 규모
- 일본의 혈관 내피 성장 인자 (VEGF) 억제제 시장 규모
- 기타 지역의 혈관 내피 성장 인자 (VEGF) 억제제 시장 규모
・성장 요인/과제/동향
・기업 현황
・기업 분석
Technavio 사는 이익, 가격, 경쟁, 프로모션과 같은 주요 매개 변수를 분석하여, 다수의 소스로부터 데이터를 조사, 통합 및 합산하여 혈관 내피 성장 인자 (VEGF) 억제제 시장에 대한 상세하고 종합적인 결과를 제공합니다. 또한, 주요 산업의 영향 요인을 분석하여 시장의 다양한 관점을 제시합니다. 제시된 데이터는 포괄적이고 신뢰할 수 있으며, 1차 및 2차에 걸친 광범위한 조사 결과입니다. 덧붙여 Technavio 사의 시장 조사 보고서는 정확한 혈관 내피 성장 인자 (VEGF) 억제제 시장 성장을 예측하기 위해, 정성적 및 정량적 조사를 사용하여, 명확한 경쟁 현황과 상세한 벤더 선택 방법 및 분석을 제공합니다. |
■ 보고서 개요Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market 2023-2027Technavio has been monitoring the vascular endothelial growth factor (VEGF) inhibitors market and is forecast to grow by $ 10400.61 mn during 2022-2027, accelerating at a CAGR of 7.76% during the forecast period. Our report on the vascular endothelial growth factor (VEGF) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high target affinity and specificity of VEGF inhibitors, promising pipeline and expected launches, and strategic alliances.
Technavio’s vascular endothelial growth factor (VEGF) inhibitors market is segmented as below:
By Application
• Oncology
• Ophthalmology
By Type
• VEGF-A inhibitor
• VEGF-B inhibitor
• VEGF-C inhibitor
• VEGF-D inhibitor
By Geography
• North America
• Europe
• Asia
• Rest of World (ROW)
This study identifies the growing popularity of combination therapies as one of the prime reasons driving the vascular endothelial growth factor (VEGF) inhibitors market growth during the next few years. Also, the development of novel drug delivery systems and growing awareness about oncology and ophthalmology will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the vascular endothelial growth factor (VEGF) inhibitors market covers the following areas:
• Vascular endothelial growth factor (VEGF) inhibitors market sizing
• Vascular endothelial growth factor (VEGF) inhibitors market forecast
• Vascular endothelial growth factor (VEGF) inhibitors market industry analysis
Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading vascular endothelial growth factor (VEGF) inhibitors market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bausch Health Co Inc., Bayer AG, Bristol Myers Squibb Co., Clovis Oncology, Eisai Co. Ltd., Eli Lilly and Co., Exelixis Inc., F. Hoffmann La Roche Ltd., LG Chem Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., Viatris Inc., and Xbrane Biopharma AB. Also, the vascular endothelial growth factor (VEGF) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
■ 보고서 목차• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market by Geography
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global vascular endothelial growth factor (VEGF) inhibitors market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global vascular endothelial growth factor (VEGF) inhibitors market 2017 – 2021 ($ million)
o 4.2 Application Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Application Segment 2017 – 2021 ($ million)
o 4.3 Type Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Type Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Application
o 6.1 Market segments
o Exhibit 30: Chart on Application – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Application – Market share 2022-2027 (%)
o 6.2 Comparison by Application
o Exhibit 32: Chart on Comparison by Application
o Exhibit 33: Data Table on Comparison by Application
o 6.3 Oncology – Market size and forecast 2022-2027
o Exhibit 34: Chart on Oncology – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Oncology – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Oncology – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Oncology – Year-over-year growth 2022-2027 (%)
o 6.4 Ophthalmology – Market size and forecast 2022-2027
o Exhibit 38: Chart on Ophthalmology – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Ophthalmology – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Ophthalmology – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Ophthalmology – Year-over-year growth 2022-2027 (%)
o 6.5 Market opportunity by Application
o Exhibit 42: Market opportunity by Application ($ million)
• 7 Market Segmentation by Type
o 7.1 Market segments
o Exhibit 43: Chart on Type – Market share 2022-2027 (%)
o Exhibit 44: Data Table on Type – Market share 2022-2027 (%)
o 7.2 Comparison by Type
o Exhibit 45: Chart on Comparison by Type
o Exhibit 46: Data Table on Comparison by Type
o 7.3 VEGF-A inhibitor – Market size and forecast 2022-2027
o Exhibit 47: Chart on VEGF-A inhibitor – Market size and forecast 2022-2027 ($ million)
o Exhibit 48: Data Table on VEGF-A inhibitor – Market size and forecast 2022-2027 ($ million)
o Exhibit 49: Chart on VEGF-A inhibitor – Year-over-year growth 2022-2027 (%)
o Exhibit 50: Data Table on VEGF-A inhibitor – Year-over-year growth 2022-2027 (%)
o 7.4 VEGF-B inhibitor – Market size and forecast 2022-2027
o Exhibit 51: Chart on VEGF-B inhibitor – Market size and forecast 2022-2027 ($ million)
o Exhibit 52: Data Table on VEGF-B inhibitor – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Chart on VEGF-B inhibitor – Year-over-year growth 2022-2027 (%)
o Exhibit 54: Data Table on VEGF-B inhibitor – Year-over-year growth 2022-2027 (%)
o 7.5 VEGF-C inhibitor – Market size and forecast 2022-2027
o Exhibit 55: Chart on VEGF-C inhibitor – Market size and forecast 2022-2027 ($ million)
o Exhibit 56: Data Table on VEGF-C inhibitor – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Chart on VEGF-C inhibitor – Year-over-year growth 2022-2027 (%)
o Exhibit 58: Data Table on VEGF-C inhibitor – Year-over-year growth 2022-2027 (%)
o 7.6 VEGF-D inhibitor – Market size and forecast 2022-2027
o Exhibit 59: Chart on VEGF-D inhibitor – Market size and forecast 2022-2027 ($ million)
o Exhibit 60: Data Table on VEGF-D inhibitor – Market size and forecast 2022-2027 ($ million)
o Exhibit 61: Chart on VEGF-D inhibitor – Year-over-year growth 2022-2027 (%)
o Exhibit 62: Data Table on VEGF-D inhibitor – Year-over-year growth 2022-2027 (%)
o 7.7 Market opportunity by Type
o Exhibit 63: Market opportunity by Type ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 65: Chart on Market share by geography 2022-2027 (%)
o Exhibit 66: Data Table on Market share by geography 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 67: Chart on Geographic comparison
o Exhibit 68: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 69: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 70: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 71: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 72: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 73: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 74: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 75: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 76: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 77: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 78: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 79: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 80: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 81: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 82: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 83: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 84: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 85: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 86: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 87: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 88: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 Canada – Market size and forecast 2022-2027
o Exhibit 89: Chart on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 90: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 91: Chart on Canada – Year-over-year growth 2022-2027 (%)
o Exhibit 92: Data Table on Canada – Year-over-year growth 2022-2027 (%)
o 9.9 UK – Market size and forecast 2022-2027
o Exhibit 93: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 94: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 95: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 96: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.10 Germany – Market size and forecast 2022-2027
o Exhibit 97: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 98: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 99: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 100: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.11 Japan – Market size and forecast 2022-2027
o Exhibit 101: Chart on Japan – Market size and forecast 2022-2027 ($ million)
o Exhibit 102: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
o Exhibit 103: Chart on Japan – Year-over-year growth 2022-2027 (%)
o Exhibit 104: Data Table on Japan – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity by geography
o Exhibit 105: Market opportunity by geography ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 106: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 107: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 108: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 109: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 110: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 111: Matrix on vendor position and classification
o 12.3 AbbVie Inc.
o Exhibit 112: AbbVie Inc. – Overview
o Exhibit 113: AbbVie Inc. – Product / Service
o Exhibit 114: AbbVie Inc. – Key news
o Exhibit 115: AbbVie Inc. – Key offerings
o 12.4 Amgen Inc.
o Exhibit 116: Amgen Inc. – Overview
o Exhibit 117: Amgen Inc. – Product / Service
o Exhibit 118: Amgen Inc. – Key offerings
o 12.5 AstraZeneca Plc
o Exhibit 119: AstraZeneca Plc – Overview
o Exhibit 120: AstraZeneca Plc – Product / Service
o Exhibit 121: AstraZeneca Plc – Key news
o Exhibit 122: AstraZeneca Plc – Key offerings
o 12.6 Bausch Health Co Inc.
o Exhibit 123: Bausch Health Co Inc. – Overview
o Exhibit 124: Bausch Health Co Inc. – Business segments
o Exhibit 125: Bausch Health Co Inc. – Key news
o Exhibit 126: Bausch Health Co Inc. – Key offerings
o Exhibit 127: Bausch Health Co Inc. – Segment focus
o 12.7 Bayer AG
o Exhibit 128: Bayer AG – Overview
o Exhibit 129: Bayer AG – Business segments
o Exhibit 130: Bayer AG – Key news
o Exhibit 131: Bayer AG – Key offerings
o Exhibit 132: Bayer AG – Segment focus
o 12.8 Bristol Myers Squibb Co.
o Exhibit 133: Bristol Myers Squibb Co. – Overview
o Exhibit 134: Bristol Myers Squibb Co. – Product / Service
o Exhibit 135: Bristol Myers Squibb Co. – Key news
o Exhibit 136: Bristol Myers Squibb Co. – Key offerings
o 12.9 Eisai Co. Ltd.
o Exhibit 137: Eisai Co. Ltd. – Overview
o Exhibit 138: Eisai Co. Ltd. – Business segments
o Exhibit 139: Eisai Co. Ltd. – Key news
o Exhibit 140: Eisai Co. Ltd. – Key offerings
o Exhibit 141: Eisai Co. Ltd. – Segment focus
o 12.10 Eli Lilly and Co.
o Exhibit 142: Eli Lilly and Co. – Overview
o Exhibit 143: Eli Lilly and Co. – Product / Service
o Exhibit 144: Eli Lilly and Co. – Key offerings
o 12.11 F. Hoffmann La Roche Ltd.
o Exhibit 145: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 146: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 147: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 148: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 149: F. Hoffmann La Roche Ltd. – Segment focus
o 12.12 Merck and Co. Inc.
o Exhibit 150: Merck and Co. Inc. – Overview
o Exhibit 151: Merck and Co. Inc. – Business segments
o Exhibit 152: Merck and Co. Inc. – Key news
o Exhibit 153: Merck and Co. Inc. – Key offerings
o Exhibit 154: Merck and Co. Inc. – Segment focus
o 12.13 Novartis AG
o Exhibit 155: Novartis AG – Overview
o Exhibit 156: Novartis AG – Business segments
o Exhibit 157: Novartis AG – Key offerings
o Exhibit 158: Novartis AG – Segment focus
o 12.14 Pfizer Inc.
o Exhibit 159: Pfizer Inc. – Overview
o Exhibit 160: Pfizer Inc. – Product / Service
o Exhibit 161: Pfizer Inc. – Key news
o Exhibit 162: Pfizer Inc. – Key offerings
o 12.15 Regeneron Pharmaceuticals Inc.
o Exhibit 163: Regeneron Pharmaceuticals Inc. – Overview
o Exhibit 164: Regeneron Pharmaceuticals Inc. – Product / Service
o Exhibit 165: Regeneron Pharmaceuticals Inc. – Key offerings
o 12.16 Sanofi SA
o Exhibit 166: Sanofi SA – Overview
o Exhibit 167: Sanofi SA – Business segments
o Exhibit 168: Sanofi SA – Key news
o Exhibit 169: Sanofi SA – Key offerings
o Exhibit 170: Sanofi SA – Segment focus
o 12.17 Takeda Pharmaceutical Co. Ltd.
o Exhibit 171: Takeda Pharmaceutical Co. Ltd. – Overview
o Exhibit 172: Takeda Pharmaceutical Co. Ltd. – Product / Service
o Exhibit 173: Takeda Pharmaceutical Co. Ltd. – Key news
o Exhibit 174: Takeda Pharmaceutical Co. Ltd. – Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 175: Inclusions checklist
o Exhibit 176: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 177: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 178: Research methodology
o Exhibit 179: Validation techniques employed for market sizing
o Exhibit 180: Information sources
o 13.5 List of abbreviations
o Exhibit 181: List of abbreviations
Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market by Geography
Exhibits5: Executive Summary – Chart on Market Segmentation by Application
Exhibits6: Executive Summary – Chart on Market Segmentation by Type
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global vascular endothelial growth factor (VEGF) inhibitors market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Application Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Type Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Application – Market share 2022-2027 (%)
Exhibits31: Data Table on Application – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Application
Exhibits33: Data Table on Comparison by Application
Exhibits34: Chart on Oncology – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Oncology – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Oncology – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Oncology – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Ophthalmology – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Ophthalmology – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Ophthalmology – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Ophthalmology – Year-over-year growth 2022-2027 (%)
Exhibits42: Market opportunity by Application ($ million)
Exhibits43: Chart on Type – Market share 2022-2027 (%)
Exhibits44: Data Table on Type – Market share 2022-2027 (%)
Exhibits45: Chart on Comparison by Type
Exhibits46: Data Table on Comparison by Type
Exhibits47: Chart on VEGF-A inhibitor – Market size and forecast 2022-2027 ($ million)
Exhibits48: Data Table on VEGF-A inhibitor – Market size and forecast 2022-2027 ($ million)
Exhibits49: Chart on VEGF-A inhibitor – Year-over-year growth 2022-2027 (%)
Exhibits50: Data Table on VEGF-A inhibitor – Year-over-year growth 2022-2027 (%)
Exhibits51: Chart on VEGF-B inhibitor – Market size and forecast 2022-2027 ($ million)
Exhibits52: Data Table on VEGF-B inhibitor – Market size and forecast 2022-2027 ($ million)
Exhibits53: Chart on VEGF-B inhibitor – Year-over-year growth 2022-2027 (%)
Exhibits54: Data Table on VEGF-B inhibitor – Year-over-year growth 2022-2027 (%)
Exhibits55: Chart on VEGF-C inhibitor – Market size and forecast 2022-2027 ($ million)
Exhibits56: Data Table on VEGF-C inhibitor – Market size and forecast 2022-2027 ($ million)
Exhibits57: Chart on VEGF-C inhibitor – Year-over-year growth 2022-2027 (%)
Exhibits58: Data Table on VEGF-C inhibitor – Year-over-year growth 2022-2027 (%)
Exhibits59: Chart on VEGF-D inhibitor – Market size and forecast 2022-2027 ($ million)
Exhibits60: Data Table on VEGF-D inhibitor – Market size and forecast 2022-2027 ($ million)
Exhibits61: Chart on VEGF-D inhibitor – Year-over-year growth 2022-2027 (%)
Exhibits62: Data Table on VEGF-D inhibitor – Year-over-year growth 2022-2027 (%)
Exhibits63: Market opportunity by Type ($ million)
Exhibits64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits65: Chart on Market share by geography 2022-2027 (%)
Exhibits66: Data Table on Market share by geography 2022-2027 (%)
Exhibits67: Chart on Geographic comparison
Exhibits68: Data Table on Geographic comparison
Exhibits69: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits70: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits71: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits72: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits73: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits74: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits75: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits76: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits77: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits78: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits79: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits80: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits81: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits82: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits83: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits84: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits85: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits86: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits87: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits88: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits89: Chart on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits90: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits91: Chart on Canada – Year-over-year growth 2022-2027 (%)
Exhibits92: Data Table on Canada – Year-over-year growth 2022-2027 (%)
Exhibits93: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits94: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits95: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits96: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits97: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits98: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits99: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits100: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits101: Chart on Japan – Market size and forecast 2022-2027 ($ million)
Exhibits102: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
Exhibits103: Chart on Japan – Year-over-year growth 2022-2027 (%)
Exhibits104: Data Table on Japan – Year-over-year growth 2022-2027 (%)
Exhibits105: Market opportunity by geography ($ million)
Exhibits106: Impact of drivers and challenges in 2022 and 2027
Exhibits107: Overview on Criticality of inputs and Factors of differentiation
Exhibits108: Overview on factors of disruption
Exhibits109: Impact of key risks on business
Exhibits110: Vendors covered
Exhibits111: Matrix on vendor position and classification
Exhibits112: AbbVie Inc. – Overview
Exhibits113: AbbVie Inc. – Product / Service
Exhibits114: AbbVie Inc. – Key news
Exhibits115: AbbVie Inc. – Key offerings
Exhibits116: Amgen Inc. – Overview
Exhibits117: Amgen Inc. – Product / Service
Exhibits118: Amgen Inc. – Key offerings
Exhibits119: AstraZeneca Plc – Overview
Exhibits120: AstraZeneca Plc – Product / Service
Exhibits121: AstraZeneca Plc – Key news
Exhibits122: AstraZeneca Plc – Key offerings
Exhibits123: Bausch Health Co Inc. – Overview
Exhibits124: Bausch Health Co Inc. – Business segments
Exhibits125: Bausch Health Co Inc. – Key news
Exhibits126: Bausch Health Co Inc. – Key offerings
Exhibits127: Bausch Health Co Inc. – Segment focus
Exhibits128: Bayer AG – Overview
Exhibits129: Bayer AG – Business segments
Exhibits130: Bayer AG – Key news
Exhibits131: Bayer AG – Key offerings
Exhibits132: Bayer AG – Segment focus
Exhibits133: Bristol Myers Squibb Co. – Overview
Exhibits134: Bristol Myers Squibb Co. – Product / Service
Exhibits135: Bristol Myers Squibb Co. – Key news
Exhibits136: Bristol Myers Squibb Co. – Key offerings
Exhibits137: Eisai Co. Ltd. – Overview
Exhibits138: Eisai Co. Ltd. – Business segments
Exhibits139: Eisai Co. Ltd. – Key news
Exhibits140: Eisai Co. Ltd. – Key offerings
Exhibits141: Eisai Co. Ltd. – Segment focus
Exhibits142: Eli Lilly and Co. – Overview
Exhibits143: Eli Lilly and Co. – Product / Service
Exhibits144: Eli Lilly and Co. – Key offerings
Exhibits145: F. Hoffmann La Roche Ltd. – Overview
Exhibits146: F. Hoffmann La Roche Ltd. – Business segments
Exhibits147: F. Hoffmann La Roche Ltd. – Key news
Exhibits148: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits149: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits150: Merck and Co. Inc. – Overview
Exhibits151: Merck and Co. Inc. – Business segments
Exhibits152: Merck and Co. Inc. – Key news
Exhibits153: Merck and Co. Inc. – Key offerings
Exhibits154: Merck and Co. Inc. – Segment focus
Exhibits155: Novartis AG – Overview
Exhibits156: Novartis AG – Business segments
Exhibits157: Novartis AG – Key offerings
Exhibits158: Novartis AG – Segment focus
Exhibits159: Pfizer Inc. – Overview
Exhibits160: Pfizer Inc. – Product / Service
Exhibits161: Pfizer Inc. – Key news
Exhibits162: Pfizer Inc. – Key offerings
Exhibits163: Regeneron Pharmaceuticals Inc. – Overview
Exhibits164: Regeneron Pharmaceuticals Inc. – Product / Service
Exhibits165: Regeneron Pharmaceuticals Inc. – Key offerings
Exhibits166: Sanofi SA – Overview
Exhibits167: Sanofi SA – Business segments
Exhibits168: Sanofi SA – Key news
Exhibits169: Sanofi SA – Key offerings
Exhibits170: Sanofi SA – Segment focus
Exhibits171: Takeda Pharmaceutical Co. Ltd. – Overview
Exhibits172: Takeda Pharmaceutical Co. Ltd. – Product / Service
Exhibits173: Takeda Pharmaceutical Co. Ltd. – Key news
Exhibits174: Takeda Pharmaceutical Co. Ltd. – Key offerings
Exhibits175: Inclusions checklist
Exhibits176: Exclusions checklist
Exhibits177: Currency conversion rates for US$
Exhibits178: Research methodology
Exhibits179: Validation techniques employed for market sizing
Exhibits180: Information sources
Exhibits181: List of abbreviations
|
| ※본 조사보고서 [세계의 혈관 내피 성장 인자 (VEGF) 억제제 시장 (2023년~2027년)] (코드 : IRTNTR72445-23) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 혈관 내피 성장 인자 (VEGF) 억제제 시장 (2023년~2027년)] 에 대해서 E메일 문의는 여기를 클릭하세요. |
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!
